TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04502459

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tourniquet
Description: A tourniquet is often used in total knee arthroplasty to achieve better visualization, reduce intra-operative bleeding and facilitate cement interdigitation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tourniquet
Description: A tourniquet is often used in total knee arthroplasty to achieve better visualization, reduce intra-operative bleeding and facilitate cement interdigitation
Study: NCT04513366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL-212 high-dose
Description: IV infusion of SEL-212 high-dose every 28 days for a total of up to 12 infusions

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: IV infusion of Normal Saline every 28 days for a total of up to 12 infusions
Study: NCT00741338

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Laronidase
Description: 0.058 mg/kg - 0.58 mg/kg IV infusion weekly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Laronidase
Description: 0.058 mg/kg - 0.58 mg/kg IV infusion weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CsA)
Description: Orally three times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CsA)
Description: Orally three times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine (Aza)
Description: Orally either every day for Cohort 1 or every other day for Cohort 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine (Aza)
Description: Orally either every day for Cohort 1 or every other day for Cohort 2.
Study: NCT03802071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab+doxorubicin cobination
Description: Durvalumab 1500mg IV Doxorubicin 75mg/m2 IV D1 Q3weeks (up to 8cycles)
Study: NCT00970593

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OAP-189
Description: Group 1: OAP-189 BID (0.2 mg BID) x 7 days Group 2: OAP-189 (0.4 mg BID) x 7 days Group 3: OAP-189 QD (0.9 mg x 7 days followed by 1.2 mg x 7 days; MR formulation) Group 4: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; MR formulation) Group 5: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; different MR formulation) Group 6: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; different MR formulation)
Study: NCT03602859

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Niraparib-Placebo
Description: Participants will receive oral capsules of niraparib-placebo as a unit dosage strength of 100 mg.
Study: NCT04450329

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SB15 (Proposed aflibercept biosimilar)
Description: Subjects randomized into SB15 group will receive SB15 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48. Starting at Week 32, subjects transited from Eylea to SB15 will receive SB15 2 mg (0.05 mL) via intravitreal injection every 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB15 (Proposed aflibercept biosimilar)
Description: Subjects randomized into SB15 group will receive SB15 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48. Starting at Week 32, subjects transited from Eylea to SB15 will receive SB15 2 mg (0.05 mL) via intravitreal injection every 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eylea (Aflibercept)
Description: Subjects randomized into Eylea group will receive Eylea 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48.
Study: NCT00970593

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Description: Group 1 \& 2: PBO x 7 days BID Group 3: PBO QD x 14 days Group 4: PBO QD x 14 days Group 5: PBO QD x 14 days Group 6: PBO QD x 14 days
Study: NCT03132233

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beta-hydroxybutyrate calcium and magnesium salt
Description: Exogenous ketone body in mineral salt form.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo powder
Description: matched placebo powder to the IMP.
Study: NCT03011593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Support Product
Description: Nutrition support product contains macronutrients, micronutrients, glutamine, and prebiotics. Product is in powder form (41 grams per serving) and is mixed with water or juice before consumption. Taken orally as a nutritional shake twice per day.
Study: NCT00638651

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imiquimod, 5% cream
Description: 2 weeks after the laser procedure the imiquimod will be applied 3 times a week for one month
Study: NCT02792569

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of ovarian cortical tissue
Description: Biopsies will be taken from either right or left side. The cortical tissue will be isolated and fragmented in 1x1 mm2 pieces, followed by auto-transplantation to a peritoneal pocket.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of ovarian cortical tissue
Description: Biopsies will be taken from either right or left side. The cortical tissue will be isolated and fragmented in 1x1 mm2 pieces, followed by auto-transplantation to a peritoneal pocket.
Study: NCT03887364

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group A-Diaphragmatic breathing
Description: Patient was in casual and agreeable position in which gravity helped the stomach, for example, a semi fowler's position. Hand was put on the rectus abdominis just beneath the foremost costal edge and requested that the patient take in gradually and profoundly through the nose. Persistent was told to keep the shoulder casual and upper chest very, enabling the belly to rise marginally. At that point persistent was guided to remain loose and breathed out gradually through the mouth. The patient rehearsed this 3 to 4 times and the rest time frame was given so patient couldn't hyperventilate.This group was given 10 reps of 3 sets with 4 weeks of follow up
Study: NCT02151045

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non target epidural infiltration done at L3-L4 stage
Description: For patients included in control arm, a non target posterior epidural space infiltration of corticoids will be done at L3-L4 stage on scan control

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural infiltration on contact of disco radicular conflict
Description: For patients included in experimental arm, an epidural infiltration of corticoids will be done in lateral on contact of disco radicular conflict on scan control.
Study: NCT03098992

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fotona Dynamis Er:YAG Laser System
Description: Treatment of urodynamic proven stress urinary incontinence using the Fotona Dynamis Er:YAG Laser System in the active arm
Study: NCT03887364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group B-Icing and Airflow Stimulation
Description: Patient was lying comfortable in semi fowler position. Facial muscle icing was given using ice pack wrapped in cloth over cheeks and nose in butterfly pattern and over forehead for 5 minutes. Ice pack was applied on the patients face (around the cheek \& nose) and accessory muscles (sternocleidomastoid muscles, upper trapezius) for single session of 5 to 10 minutes.~After that airflow stimulation was given with the help of table fan. Table fan was placed on the central area of face. Duration of the fan for the patient was at least 5 minutes to relive dyspnea and distance kept approximate of 60 centimeter (2 rulers).
Study: NCT00395421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NM283 plus Peg-IFNα-2a
Description: 200 mg QD 180 µg QW
Study: NCT01769820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: studies 1\&2:0.75mg twice daily for 5 days, starting on day LH (Luteinising Hormone)+8 of menstrual cycle; Study 3 (adaptive) 0.2,0.4,0.5,0.75,0.8,0.9mg twice daily as above
Study: NCT01951339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 100 mg sitagliptin
Study: NCT01769820

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01951339

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Active Comparator~2mg glimepiride
Study: NCT04502459

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tourniquet
Description: A tourniquet is often used in total knee arthroplasty to achieve better visualization, reduce intra-operative bleeding and facilitate cement interdigitation
Study: NCT01951339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 mg placebo once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 100 mg placebo once daily for three months
Study: NCT04839120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MDPK67b
Description: Two subgroups (Panels A and Panel B) of four subjects were to be randomly allocated either to placebo or to three increasing doses of MDPK67b, administered as single infusion at intervals of at least two weeks during the first three periods with the last period involving four repeated doses administered at three-day intervals.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two subgroups (Panel A and Panel B) of four subjects were to be randomly allocated either to placebo or to three increasing doses of MDPK67b, administered as single infusion at intervals of at least two weeks during the first three periods with the last period involving four repeated doses administered at three-day intervals.
Study: NCT02387008

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GUIDOR® membrane with FDBA
Description: horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GUIDOR® membrane
Description: horizontal bone augmentation with synthetic GUIDOR® membrane

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bio-Gide® membrane with FDBA
Description: xenograft BioGide® membrane + FDBA
Study: NCT02677857

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Common intervention components for Lifestyle
Description: Participants in these conditions will receive standard care and one of the Lifestyle conditions. There are several components that will be identical for both Lifestyle conditions. These components include treatment structure, dietary goals, and cognitive behavioral strategies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Common intervention components for Lifestyle
Description: Participants in these conditions will receive standard care and one of the Lifestyle conditions. There are several components that will be identical for both Lifestyle conditions. These components include treatment structure, dietary goals, and cognitive behavioral strategies.
Study: NCT00025246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04394936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: 100 mg guselkumab administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Sodiumchloride 0,9% solution for injection
Study: NCT00967096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin for Bone marrow transplant patients
Study: NCT03274986

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACRYSOF® IQ Extended Depth of Focus IOL
Description: Implantable IOL intending to extend the depth of focus and provide continuous functional vision from distance to near while maintaining distance vision and a visual disturbance profile comparable to a monofocal IOL.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ACRYSOF® IQ Monofocal IOL
Description: Monofocal IOL implanted for long-term use over the lifetime of the pseudophakic subject

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: IOL bilateral implantation
Study: NCT03790098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Restorative-Flow Yoga
Description: Restorative yoga consists of a series of gentle poses, supported by props, with an emphasis on breathing and relaxing; as opposed to stretching or contracting muscles, it is designed to support muscles. Flow yoga consists of a series of linked poses synchronized with the breath.
Study: NCT02663297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATLCAR.CD30 cells
Description: Three dose levels will be evaluated:~Group One, 2x10\^7 cells/m\^2 (maximum dose 5x10\^7 cells)~Group Two, 1x10\^8 cells/m\^2 (maximum dose 2.5x10\^8 cells)~Group Three, 2x10\^8 cells/m\^2 (maximum dose 5x10\^8 cells)
Study: NCT03274986

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: IOL bilateral implantation
Study: NCT03098992

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Fotona Dynamis Er:YAG Laser System with sham handpience
Description: Sham treatment with a sham handpiece and parameter presentations masked
Study: NCT02081664

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: lifestyle intervention
Study: NCT03925909

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eriocitrin
Description: The responsible nutritionists will do 1) Anthropometric Assessment, in which weight data will be collected (kg); height (m); waist circumference (cm), waist circumference (cm) and hip circumference (cm), muscle mass (kg /%) and percentage of fat by means of bioimpedance equipment; 2) Dietary assessment, which will be performed through a 24-hour Food Recall, a 3-day Food Record and a Food Consumption Frequency Questionnaire; 3) Evaluation of the microbiota, for which stool will be collected from the last 24 hours on the day before the beginning of the experiment and at the end of the study (week 12); 3) Biochemical evaluation, which includes the collection of 30 mL of blood to be performed by trained and qualified technicians.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eriocitrin
Description: The responsible nutritionists will do 1) Anthropometric Assessment, in which weight data will be collected (kg); height (m); waist circumference (cm), waist circumference (cm) and hip circumference (cm), muscle mass (kg /%) and percentage of fat by means of bioimpedance equipment; 2) Dietary assessment, which will be performed through a 24-hour Food Recall, a 3-day Food Record and a Food Consumption Frequency Questionnaire; 3) Evaluation of the microbiota, for which stool will be collected from the last 24 hours on the day before the beginning of the experiment and at the end of the study (week 12); 3) Biochemical evaluation, which includes the collection of 30 mL of blood to be performed by trained and qualified technicians.
Study: NCT03640585

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Music therapy
Description: Only the neurodevelopmental therapy was applied in the second group without music. A total of 15 treatments were administered for 5 weeks, 3 sessions per week for all patients. The sessions were 45 minutes.
Study: NCT01868386

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated therapy
Description: Shorter courses of increasing doses of radiation therapy will be assessed in each subsequent arm

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated therapy
Description: Shorter courses of increasing doses of radiation therapy will be assessed in each subsequent arm

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated therapy
Description: Shorter courses of increasing doses of radiation therapy will be assessed in each subsequent arm

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated therapy
Description: Shorter courses of increasing doses of radiation therapy will be assessed in each subsequent arm
Study: NCT02731612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lurasidone
Description: Atypical Antipsychotic
Study: NCT03640585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Only the neurodevelopmental therapy was applied in the second group without music. A total of 15 treatments were administered for 5 weeks, 3 sessions per week for all patients. The sessions were 45 minutes.
Study: NCT05150353

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: MRI
Description: Wrist MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Wrist MRI
Study: NCT01393405

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Induction period (week 1-16) (Open label):~25 mg MTX sq once weekly + Steroid taper + 1 mg folic acid daily~Maintenance period (week 17-48) (Randomization):~25 mg MTX sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine or Placebo sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Induction period (week 1-16) (Open label):~25 mg MTX sq once weekly + Steroid taper + 1 mg folic acid daily~Maintenance period (week 17-48) (Randomization):~25 mg MTX sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine or Placebo sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine
Study: NCT02603835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SSO2 Therapy
Description: Delivery of SSO2 Therapy for 60 minutes selectively into the left main coronary artery (LMCA) using the TherOx DownStream System along with a single use disposable device called the TherOx DownStream Cartridge and a commercially available, qualified SSO2 delivery catheter
Study: NCT01970839

Intervention type: DEVICE
Group type: OTHER
Intervention: tourniquet, sensory nerve conduction abnormality
Study: NCT01885546

Intervention type: DEVICE
Group type: OTHER
Intervention: AgaMatrix Blood Glucose Monitor
Study: NCT00549562

Intervention type: DRUG
Group type: OTHER
Intervention: Paliperidone ER
Description: Starting dose is 3 mg per day. Can be titrated up to a maximum dose of 9 mg per day.
Study: NCT01722253

Intervention type: PROCEDURE
Intervention: Electroacupuncture
Description: Electrical stimulation device with frequency 2 Hz and 'frequency scanning mode'
Study: NCT02472938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: dimethyl fumarate 120 mg capsules

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for BG00012
Study: NCT00831532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: Dimebon 5mg in healthy controls

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: Dimebon 5mg in mild hepatic impairment patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: Dimebon 5mg in moderate hepatic impairment patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: Dimebon 5mg in Severe Hepatic Impairment
Study: NCT05053529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: Session consist of total 1hour,20 min of passive mobilization, 30 minutes for Movement mirror therapy,10 minutes standard ADL activities 5 times a week and for consecutive 3 weeks in a month.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CIMT group
Description: Session consist of total 1hour ,20 min of passive mobilization, 30 min session to CIMT and 10 minutes standard ADL activities 5 times a week and for consecutive 3 weeks in a month.
Study: NCT04908670

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Understanding Pain in less than 5 minutes, and what to do about it! https://www.youtube.com/watch?v=C_3phB93rvI
Description: Watching pain neuroscience education video

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Understanding Pain in less than 5 minutes, and what to do about it! https://www.youtube.com/watch?v=C_3phB93rvI
Description: Watching pain neuroscience education video

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PA manipulation
Description: Low grade PA manipulation on the cervical, thoracic and lumbar spine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PA manipulation
Description: Low grade PA manipulation on the cervical, thoracic and lumbar spine
Study: NCT01380184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: 4 enteric-coated tablets, each containing 10 mg ridaforolimus, orally (total daily dose: 40 mg)
Study: NCT01317238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: smallpox vaccine CJ-50300
Description: Conventional CJ-50300 2.5 x 100000 pfu/dose vaccination
Study: NCT01271088

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: N-acetylcysteine
Description: N-acetylcysteine 600 mg twice a day,one week after administration of antibiotics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: N-acetylcysteine 600 mg twice a day,one week after administration of antibiotics
Study: NCT00931749

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low intensity pulsed ultrasound therapy
Description: 1 MHz, Spatial Average Intensity of 0.2 W /cm2, pulsed duty cycle 20%, 9.5 minutes, Therapeutic dose= 112.5 J/cm2. Fixed application on the medial side of the knee joint. Three sessions per week, during 2 months ( 24 sessions)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Low intensity pulsed ultrasound therapy
Description: The Ultrasound device will not have the transducer´s crystal, so no ultrasonic energy will be provided.
Study: NCT00804518

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic interval training
Description: High intensity aerobic interval training consists of 10 minutes warm up at \~60% of maximal heart rate, 4x4 minutes intervals at 90-95 % of maximal heart rate corresponding to 85-90% of VO2max) walking/running uphill on a treadmill, with three minutes active pause between the exercise bouts at 60-70% maximal heart rate. The session is terminated with 3 minutes cool down. Total exercise time is 38 minutes.The training is supervised by an exercise physiologist and the subjects train 3 times per week for 12 weeks.
Study: NCT00708942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hexaminolevulinate (HAL)
Description: Drug: hexaminolevulinate (HAL) Suppository HAL 100 mg for 3-7 hours application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo suppository, for 3-7 hours application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hexaminolevulinate (HAL)
Description: Drug: hexaminolevulinate (HAL) Ointment HAL 100 mg for 5 hours application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo ointment for 5 hours application